Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 04-11-2024 | 12-31-2023 | 10-K | |
| 2 | 08-14-2023 | 06-30-2023 | 10-Q | |
| 3 | 05-15-2023 | 03-31-2023 | 10-Q | |
| 4 | 03-14-2023 | 12-31-2022 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JMP Securities analyst Silvan Tuerkcan reiterates Notable Labs (NASDAQ:NTBL) with a Market Outperform and maintains $9 price...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $9 to $7.
The company presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patient...
Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable" or the "Company"), a clinical-stage precision oncology company deve...
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk...
Shares of Juniper Networks, Inc. (NYSE: JNPR) rose sharply in pre-market trading on Tuesday.
JMP Securities analyst Silvan Tuerkcan maintains Notable Labs (NASDAQ:NTBL) with a Market Outperform and lowers the price ta...
- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial -- Predictive Results Further Advance PPM...
